Prevalence of Low T


	Home

	Prevalence of Low T

	Symptoms and diagnosis

	Benefits of AndroGel

	Safety and monitoring

	Professional resources

	For your patients

	References

Printer version

Send to a colleague

Text size

Prevalence in U.S.

Low T affects over 13 million men in the U.S. over the age of 45³

12.5 million men with Low T are not treated.

Comorbid prevalence

Certain comorbidities may increase odds of also having Low T

The odds of having hypogonadism were significantly higher in men with obesity, diabetes, hypertension, or hyperlipidemia than those without these conditions.³

Diabetes and Low T

Studies show 33% to 50% of male patients with diabetes may have Low T.^3,5,6

Diabetic men are also more likely to be overweight or obese.

Hypogonadism prevalence increases with an increase in BMI.³

Treatment guidelines for diabetics

If your patient is diabetic, include a simple testosterone test in his lab workup.

The Endocrine Society recommends that total testosterone should be measured for all male type 2 diabetic patients during routine lab workup.⁸

In general, if total testosterone is <300 ng/dL, testosterone replacement therapy may provide benefits, if there are no contraindications to treatment.¹

HIV/AIDS and Low T

Low T also occurs in 21% of HIV-infected men and men with AIDS.^9,10

Symptoms and diagnosis


		AndroGel is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. Androgens are contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate. AndroGel is not indicated for use in women. Geriatric patients treated with androgens may be at an increased risk for the development of prostatic hyperplasia and prostatic carcinoma. The most frequent adverse events reported by ≥5% of patients associated with the consistent use of AndroGel included abnormal lab test, acne, prostate disorder, and application site reaction.

This information is intended for residents of the United States.
For international product information please visit us at http://www.solvay.com.
© 2007 Solvay Pharmaceuticals, Inc.